More effective and targeted cancer therapies with improved patient outcomes.
There is an unmet need in multiple cancers for improved efficacy. Current treatments with antibody alone have led to poor patient responses, and not all ADCs function adequately.
Antibody drug conjugates (ADCs), which combine an antibody with chemotherapeutic drugs to make cancer treatment more targeted, effective and less damaging to healthy tissue, are set to work better than ever.
Our antibody-drug-polymer therapies, have improved efficacy and pharmacokinetics than current ADCs, thus lowering drug doses, they allow for use of multiple drugs and are expected to lead to fewer side effects.
- Advanced biological‐polymeric materials to treat human disease
- RAFT (reversible addition and fragmentation chain transfer) polymerisation technology leads to defined polymeric carriers with the ability to tailor composition and structure
- Stable, safe, and reliable polymeric scaffold for attachment of biologically active compounds
- Optimise the pharmacokinetic properties of therapeutic drugs and proteins
- Outstanding efficacy and pharmacokinetics, in models of disease
- Drug loaded antibody-polymer conjugates have performed well in animal models of cancer burden
- Requires pharmaceutical or biotech partner to go to next stage.
- Only three commercial ADC based drugs available in 2013, sales approx. USD450 million.
- Applications across a range of diseases, extending towards diagnostic and imaging therapies
- Available ADC drugs: Mylotarg (Pfizer), Adcetris (Seattle Genetics/Takeda), Kadcyla (Roche/Genentech)
- With around 12 expected new ADC launches over the next 10 years, the overall market is expected to reach USD10.4 billion by 2024
- Preferred model is industry partnership is a Joint Venture with pharmaceutical / biotech company.
Patent filed January 2017 – Biocompatible and hydrophilic polymerconjugate for targeted delivery of an agent.
Our team collectively has experience in organic chemistry, polymer chemistry, protein chemistry and bioconjugation. Our research interests include, methods to conjugate small molecules, or polymers to proteins such as antibodies or antibody fragments.